The threat comes as Trump's administration pressures pharmaceutical companies to lower drug prices for Americans.

In a pooled analysis of three randomized trials, CPAP had overall null cardiovascular effects in patients with obstructive ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

Eli Lilly offers an annual dividend yield of 0.78%. So, how can investors exploit its dividend yield to pocket a regular $500 ...

Eli Lilly is eligible for 100M in tax credits to expand its Pleasant Prairie facility, adding 750 jobs and boosting Wisconsin ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...